Bone: Use of bisphosphonates in children-proceed with caution (Q83835502)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Bone: Use of bisphosphonates in children-proceed with caution (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Joan C Marini

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

1 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Endocrinology

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

241-243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

Clinical review 1: Bisphosphonate use in childhood osteoporosis

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Should children with osteogenesis imperfecta be treated with bisphosphonates?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Economic return of clinical trials performed under the pediatric exclusivity program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Bisphosphonate-induced osteopetrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

Giant osteoclast formation and long-term oral bisphosphonate therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.58

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2009.58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19444252%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference